A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

Inclusion Criteria: * Diagnosis of chronic hepatitis C genotype 1a or 1b * Male or female aged 18 to 65 years, inclusive * Compensated liver disease without evidence of cirrhosis * No evidence of type 1 or 2 diabetes mellitus, lipodystrophy or polycystic ovary syndrome * No history or presence of autoimmune or lymphoproliferative disease or hemoglobinopathies * Stable medication doses for 1 month for the chronic disease if subjects have chronic diseases, including but not limited to hypertension and dyslipidemia Exclusion Criteria: * History of previous treatment of hepatitis C * Currently use medication for psychiatric illness including depression, suicidal ideation, and psychosis * History or presence of chronic liver disease * History of drug or alcohol abuse within the past year * Evidence of active illicit drug use * Clinically significant abnormal electrocardiogram (ECG) or rhythm strip * Female subject who has a positive urine pregnancy test or who is lactating